This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Fei Chen, PhD
Managing Partner at Lilly Asia Ventures


Dr. Fei Chen is a Managing Partner with Lilly Asia Ventures (LAV) and responsible for LAV’s investment decision and fund management.  Since 2009 Dr. Chen’s investments list includes leading Chinese biotech companies such as Betta Pharma (300558.SZSE), Chipscreen Bio (688321.SHSE), RemeGen (09995.HKSE), Impact Therapeutics, Kechow Pharma, Inventis Bio, Edigene, Gracell Bio (GRCL.US), Allist (688578.SHSE), Dizal, ImmuneOnco, Connect (CNTB.US), and CARsgen etc., leading Chinese specialty pharms such as BrightGene (688166.SHSE), Sinqi Eye (300573.SZSE), Omni, Huawei, Ausun Pharma (603229.SHSE) etc., and leading medtech/IVD/CRO companies such as Pins, Microtech, Singlera Genomics, Purcutek, Peijia (09996.HKSE), YHLo Bio, Xihua Scientific, Geneseeq, Forqaly, LavaMed, BGImNGS, Virtue Dx, TargetingOne etc.

Dr. Chen holds a Ph.D. in molecular genetics and a Bachelor’s degree in biology from Fudan University, he is a member of BayHelix Group.

Agenda Sessions

  • Partnering Bootcamp LIVE - Session 2: The Investors’ Perspectives and Advice on Healthcare IPOs